$LLY

Jonsson Patrik sold $7.6M of LLY

Jonsson Patrik (EVP & President, LLY Int'l) sold 6,500 shares of ELI LILLY & Co (LLY) at $1175.10 ($7.64M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jonsson Patrik
Published Aug 18, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not include guidance, trial results, regulatory actions, or deal terms.

02

Market read

Traders may note insider selling, but the 10b5-1 framing and lack of fundamental updates make it low-signal for price action.

03

What to watch

The disclosure does not indicate whether sales were part of broader diversification, tax planning, or option exercises, limiting inference beyond the fact of selling.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP and President Jonsson sold 6,500 shares at $1,175.10 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, unusually large or clustered insider selling can be interpreted as private caution, though this article provides no comparative context.

Key entities

  • ELI LILLY & Co

    Subject of the Form 4 insider sale by EVP and President, LLY International, Patrik Jonsson.

  • Patrik Jonsson

    EVP and President, LLY International, reported an open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMedAI 8/10

Upper Macungie OKs Eli Lilly final land development plan

Upper Macungie Township approved Eli Lilly's final land development plan for a $3.5 billion pharmaceutical plant. The 797,432-square-foot facility will create 2,000 construction jobs and involve final assembly of injectable medicines. The project will be completed in phases, with the first phase including an amenities building and visitor center.

$LLYMedAI 8/10

Great News for Eli Lilly Stock Investors

Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, became the world's best-selling drug, contributing 65% of Q2 revenue. Clinical trials showed tirzepatide combined with Taltz improved psoriasis and psoriatic arthritis symptoms, expanding potential uses beyond diabetes and obesity. Eli Lilly is testing tirzepatide in other conditions, aiming to secure broader insurance coverage and mitigate competition risks.

$TAKHighAI 8/10

FDA Neurology Digest: August 2026

In August 2026, the FDA approved Oveporexton (Takeda) for narcolepsy, a first-in-class drug restoring orexin signaling. It also cleared Roche's Elecsys Phospho-Tau test (with Eli Lilly) for Alzheimer's assessment and C2N Diagnostics' PrecivityAD2 for younger adults. REGENXBIO's Hunter syndrome therapy was put on hold, while Cellenkos' ALS therapy received Fast Track designation. Lantheus' Tauklarify, a tau-targeted imaging agent, was approved for AD evaluation.

$LLYMedAI 8/10

Eli Lilly’s Foundayo Launches in UK Amid Counterfeit Risks

Eli Lilly's GLP-1 weight-loss pill, Foundayo, is now available in UK pharmacies via private prescription, following MHRA approval. The tablet offers convenience over injectables and has shown significant weight loss in trials. Eli Lilly is working with NICE for potential NHS inclusion. Counterfeit risks are a concern, with 97% of pharmacies worried about unlicensed products. The company is exploring tech solutions for supply chain security.